COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA

Authors

  • Safina Shabbir Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Zill -e- Humayun Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Javad Yousaf Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Adnan Manzar Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Shabana Mushtaq Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan
  • Maria Yousaf Pakistan Naval Ship (PNS) Shifa Hospital, Karachi/National University of Medical Sciences (NUMS) Pakistan

Keywords:

Atorvastatin, Diabetes mellitus, Hyperlipidemia, Rosuvastatin

Abstract

Objective: To evaluate & compare the mean change in fasting serum total cholesterol and LDL-C levels from baseline, after 12 weeks of oral treatment with oral Rosuvastatin and with Atorvastatin in type 2 diabetic patients with primary hyperlipidemia.

Study Design: Cross sectional comparative study.

Place and Duration of Study: The present study was conducted in the Medicine Department, Pakistan Naval Ship, Shifa Hospital, Karachi, from Mar to Sep 2016.

Methodology: The sample was collected by non- probability convenient sampling. The total of 114 DM type 2 patients were randomly divided into two equal groups. Group A was given Rosuvastatin whereas group B was given Atorvastatin orally daily for 12 weeks along with oral treatment for diabetes. After 12 weeks, Fasting Serum Total Cholesterol and Serum LDL-C were estimated, and noted as final levels.

Results: There was greater reduction in terms of mean change in serum total cholesterol levels and low-density lipoprotein – cholesterol (LDL-C) levels with Rosuvastatin as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.

Conclusion: Rosuvastatin can significantly improve lipid profile as compared to Atorvastatin in type 2 diabetic patients with hyperlipidemia.

Downloads

Download data is not yet available.

Downloads

Published

15-12-2020

Issue

Section

Original Articles

How to Cite

1.
Shabbir S, Humayun Z- e-, Yousaf MJ, Manzar MA, Mushtaq S, Yousaf M. COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA. Pak Armed Forces Med J [Internet]. 2020 Dec. 15 [cited 2024 Jul. 19];70(6):1671-75. Available from: https://pafmj.org/PAFMJ/article/view/5866